What's Hot
View all perspectives
TheDaoIndex KDAO2011
2 years ago
Big change for #SLE Trials coming soon.
My exclusive interview w/Prof @EricFMorand. Future trials will likely incorporate this Novel Treatment Response Measurement (TRM) Tool #ACR22 @rheumnow https://t.co/TXsxJi3qhC
Bella Mehta bella_mehta
2 years ago
Our work presented at #ACR22 showing increased mast cells and tryptase activity in women with OA compared to men!
Food for thought - can simple allergy meds help in OA management?
@RheumNow abst#1642. https://t.co/cBQZU5MXeR
David Liew drdavidliew
2 years ago
Cancer risk with tofacitinib vs TNFi in RA:
we learned at #ACR21 that
CV-enriched pts: risk (ORAL Surveillance)
all comers: no risk (STAR-RA)
French national healthcare database #ACR22 looks at all comers: nothing to separate tofa and TNFi.
Risk begets risk
ABST1984 @RheumNow https://t.co/0GG04NSP3D https://t.co/nwQz7fx21M
TheDaoIndex KDAO2011
2 years ago
Based on your experience, will you attend #ACR23 next year ... @ACRheum @rheumnow
Patricia Harkins DrTrishHarkins
2 years ago
⚡️Pulmonary pulse wave transit time⚡️
👉novel non-invasive echo measure of ⬆️pulm vasc tone in pulm HTN
👉hyperuricaemic pts ⬇️pPTT sugg of pulm vasc dysfn
@FloodRachael #ACR22 Abst1788 @RheumNow https://t.co/ZEORWbqw6f
David Liew drdavidliew
2 years ago
Still for me the most interesting bit from the GLORIA study (PNL 5 add-on in RA) is the coming off of it.
Patients were able to come off their long-term low-dose prednisolone. No Sx/biochem differences vs placebo.
True #squadgoals for rheumatologists
ABST2000 #ACR22 @RheumNow https://t.co/eQLcgqA1SN https://t.co/RGTCrMhld7
Robert B Chao, MD doctorRBC
2 years ago
Cumulative dose and exposure to methotrexate were not predictors of hepatic fibrosis.
Hepatic fibrosis as measured by elastography associated with daily EtOH use.
#ACRBest Abs#2147 @RheumNow #ACR22
Bella Mehta bella_mehta
2 years ago
Peritonitis of the #FMF - misdiagnosed as acute abdomen
Acute appendicitis is the leading cause of acute abdomen in FMF
Turkish study 1655 #FMF pts
15.8% appendectomy rates!
CRP ineffective for differing FMF from appendicitis :(
@RheumNow #ACR22 abst#1839
Robert B Chao, MD doctorRBC
2 years ago
Factors associated with non-achievement of MDA in PsA pts receiving golimumab:
Baseline tender joint count, fibromyalgia, older age, smoking, high BMI
Abs#2109 @RheumNow #ACR22 https://t.co/dEzQxVtavh
Patricia Harkins DrTrishHarkins
2 years ago
‼️‼️Frailty ‼️‼️
👉Important predictor of serious infxn in RA pts on b- or tsDMARD irrespective of age ‼️‼️
@NamrataRheum illustrating yet another reason why it is so NB to evaluate 4 frailty in ALL (incl young) pts with RA
#GeriRheum
Abst2218 @RheumNow #ACR22 https://t.co/J4XQFmVoUw
Dr. Rachel Tate uptoTate
2 years ago
While there are limitations to this study (respondents over childbearing age, white, educated, insured), within 2 months of @USSupremeCourt3's overturn of Roe v Wade, 1 in 17 MTX pts experienced a barrier to getting rx filled. ABS L09 @RheumNow #ACR22 https://t.co/WuikwO1bZ9 https://t.co/4Ve0zAVxbG
Robert B Chao, MD doctorRBC
2 years ago
Early psoriasis and enthesitis response in PsA pts treated with guselkumab predicted longterm clinical response including MDA, DAPSA LDA, DAPSA50, DAPSA remission.
Pts w/o early response, only half achieved remission
Abs#2115 @RheumNow #ACR22 https://t.co/dnsQcp7cEq
Dr. Rachel Tate uptoTate
2 years ago
BKZ showed clinically meaningful improvements in efficacy outcomes in bDMARD-naïve PsA pts at Wk 16 through wk 52. No new safety signals. ABS L02 #ACR22 @RheumNow https://t.co/Dph32O7NWG https://t.co/d7Yq3JISyF
David Liew drdavidliew
2 years ago
I think this has changed my mind!
Does RA benefit from changes in diet & exercise?
RCT Reade @amsterdamumc n=77
mod active RA
https://t.co/5Iw6hYJzGK for 16w:
whole food plant-based diet/exercise/stress management
0.9 improvement in DAS28 vs placebo!
ABST1998 #ACR22 @RheumNow https://t.co/u10RqmPMPd
Robert B Chao, MD doctorRBC
2 years ago
PsA bDMARD "ranking" system by systematic literature review looked at 30 RCTs
Highest probability of achieving ACR20 and PASI90: infliximab, golimumab and bimekizumab
#ACRBest Abs#2123 @RheumNow #ACR22 https://t.co/KpW0p2KAQZ
Poster Hall